Admetsys has developed the world’s first automated glucose control system (artificial pancreas) for use in hospital and surgical care. Three clinical trial protocols attest to the system's next-generation performance: 97% control and complete prevention of dangerous low glucose levels. FDA has granted the system accelerated review. Admetsys is presently gearing up for commercial production, and for the final phase trials that will support regulatory clearance in the U.S. and Europe.